254 related articles for article (PubMed ID: 30919310)
1. Multikinase Abl/DDR/Src Inhibition Produces Optimal Effects for Tyrosine Kinase Inhibition in Neurodegeneration.
Fowler AJ; Hebron M; Missner AA; Wang R; Gao X; Kurd-Misto BT; Liu X; Moussa CE
Drugs R D; 2019 Jun; 19(2):149-166. PubMed ID: 30919310
[TBL] [Abstract][Full Text] [Related]
2. Discoidin domain receptor inhibition reduces neuropathology and attenuates inflammation in neurodegeneration models.
Hebron M; Peyton M; Liu X; Gao X; Wang R; Lonskaya I; Moussa CE
J Neuroimmunol; 2017 Oct; 311():1-9. PubMed ID: 28863860
[TBL] [Abstract][Full Text] [Related]
3. The c-Abl inhibitor, Radotinib HCl, is neuroprotective in a preclinical Parkinson's disease mouse model.
Lee S; Kim S; Park YJ; Yun SP; Kwon SH; Kim D; Kim DY; Shin JS; Cho DJ; Lee GY; Ju HS; Yun HJ; Park JH; Kim WR; Jung EA; Lee S; Ko HS
Hum Mol Genet; 2018 Jul; 27(13):2344-2356. PubMed ID: 29897434
[TBL] [Abstract][Full Text] [Related]
4. Novel Src/Abl tyrosine kinase inhibitor bosutinib suppresses neuroblastoma growth via inhibiting Src/Abl signaling.
Bieerkehazhi S; Chen Z; Zhao Y; Yu Y; Zhang H; Vasudevan SA; Woodfield SE; Tao L; Yi JS; Muscal JA; Pang JC; Guan S; Zhang H; Nuchtern JG; Li H; Li H; Yang J
Oncotarget; 2017 Jan; 8(1):1469-1480. PubMed ID: 27903968
[TBL] [Abstract][Full Text] [Related]
5. Simultaneous inhibition of c-Abl and Src kinases abrogates the exaggerated expression of profibrotic genes in cultured systemic sclerosis dermal fibroblasts.
Piera-Velazquez S; Jimenez SA
Clin Exp Rheumatol; 2018; 36 Suppl 113(4):36-44. PubMed ID: 30277861
[TBL] [Abstract][Full Text] [Related]
6. Structural mechanisms determining inhibition of the collagen receptor DDR1 by selective and multi-targeted type II kinase inhibitors.
Canning P; Tan L; Chu K; Lee SW; Gray NS; Bullock AN
J Mol Biol; 2014 Jun; 426(13):2457-70. PubMed ID: 24768818
[TBL] [Abstract][Full Text] [Related]
7. Src family kinase/abl inhibitor dasatinib suppresses proliferation and enhances differentiation of osteoblasts.
Lee YC; Huang CF; Murshed M; Chu K; Araujo JC; Ye X; deCrombrugghe B; Yu-Lee LY; Gallick GE; Lin SH
Oncogene; 2010 Jun; 29(22):3196-207. PubMed ID: 20228840
[TBL] [Abstract][Full Text] [Related]
8. Src-Abl tyrosine kinase chimeras: replacement of the adenine binding pocket of c-Abl with v-Src to swap nucleotide and inhibitor specificities.
Liu Y; Witucki LA; Shah K; Bishop AC; Shokat KM
Biochemistry; 2000 Nov; 39(47):14400-8. PubMed ID: 11087392
[TBL] [Abstract][Full Text] [Related]
9. Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells.
Remsing Rix LL; Rix U; Colinge J; Hantschel O; Bennett KL; Stranzl T; Müller A; Baumgartner C; Valent P; Augustin M; Till JH; Superti-Furga G
Leukemia; 2009 Mar; 23(3):477-85. PubMed ID: 19039322
[TBL] [Abstract][Full Text] [Related]
10. Discoidin Domain Receptor 1 is a therapeutic target for neurodegenerative diseases.
Fowler AJ; Hebron M; Balaraman K; Shi W; Missner AA; Greenzaid JD; Chiu TL; Ullman C; Weatherdon E; Duka V; Torres-Yaghi Y; Pagan FL; Liu X; Ressom H; Ahn J; Wolf C; Moussa C
Hum Mol Genet; 2020 Oct; 29(17):2882-2898. PubMed ID: 32776088
[TBL] [Abstract][Full Text] [Related]
11. ABL tyrosine kinase inhibition variable effects on the invasive properties of different triple negative breast cancer cell lines.
Chevalier C; Cannet A; Descamps S; Sirvent A; Simon V; Roche S; Benistant C
PLoS One; 2015; 10(3):e0118854. PubMed ID: 25803821
[TBL] [Abstract][Full Text] [Related]
12. Plasma and cerebrospinal fluid pharmacokinetics of vodobatinib, a neuroprotective c-Abl tyrosine kinase inhibitor for the treatment of Parkinson's disease.
Walsh RR; Damle NK; Mandhane S; Piccoli SP; Talluri RS; Love D; Yao SL; Ramanathan V; Hurko O
Parkinsonism Relat Disord; 2023 Mar; 108():105281. PubMed ID: 36717298
[TBL] [Abstract][Full Text] [Related]
13. Abrogation of transforming growth factor-β-induced tissue fibrosis in TBRIcaCol1a2Cre transgenic mice by the second generation tyrosine kinase inhibitor SKI-606 (Bosutinib).
Wermuth PJ; Jimenez SA
PLoS One; 2018; 13(5):e0196559. PubMed ID: 29718973
[TBL] [Abstract][Full Text] [Related]
14. C-Abl Inhibition; A Novel Therapeutic Target for Parkinson's Disease.
Abushouk AI; Negida A; Elshenawy RA; Zein H; Hammad AM; Menshawy A; Mohamed WMY
CNS Neurol Disord Drug Targets; 2018 Apr; 17(1):14-21. PubMed ID: 28571531
[TBL] [Abstract][Full Text] [Related]
15. The c-Abl inhibitor in Parkinson disease.
Zhou ZH; Wu YF; Wang XM; Han YZ
Neurol Sci; 2017 Apr; 38(4):547-552. PubMed ID: 28078567
[TBL] [Abstract][Full Text] [Related]
16. Reduction of Blood Amyloid-β Oligomers in Alzheimer's Disease Transgenic Mice by c-Abl Kinase Inhibition.
Estrada LD; Chamorro D; Yañez MJ; Gonzalez M; Leal N; von Bernhardi R; Dulcey AE; Marugan J; Ferrer M; Soto C; Zanlungo S; Inestrosa NC; Alvarez AR
J Alzheimers Dis; 2016 Oct; 54(3):1193-1205. PubMed ID: 27567806
[TBL] [Abstract][Full Text] [Related]
17. Second-generation Src/Abl inhibitor bosutinib effectively induces apoptosis in human esophageal squamous cell carcinoma (ESCC) cells via inhibiting Src/Abl signaling.
Ha YNE; Dai Y; Wufuer D; Pidayi M; Anasihan G; Chen L
Neoplasma; 2020 Jan; 67(1):54-60. PubMed ID: 31777258
[TBL] [Abstract][Full Text] [Related]
18. Bosutinib: a dual SRC/ABL kinase inhibitor for the treatment of chronic myeloid leukemia.
Keller G; Schafhausen P; Brummendorf TH
Expert Rev Hematol; 2009 Oct; 2(5):489-97. PubMed ID: 21083014
[TBL] [Abstract][Full Text] [Related]
19. Activity of dual SRC-ABL inhibitors highlights the role of BCR/ABL kinase dynamics in drug resistance.
Azam M; Nardi V; Shakespeare WC; Metcalf CA; Bohacek RS; Wang Y; Sundaramoorthi R; Sliz P; Veach DR; Bornmann WG; Clarkson B; Dalgarno DC; Sawyer TK; Daley GQ
Proc Natl Acad Sci U S A; 2006 Jun; 103(24):9244-9. PubMed ID: 16754879
[TBL] [Abstract][Full Text] [Related]
20. Discoidin domain receptors orchestrate cancer progression: A focus on cancer therapies.
Gao Y; Zhou J; Li J
Cancer Sci; 2021 Mar; 112(3):962-969. PubMed ID: 33377205
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
